Key result
Mobile-based cognitive behavior therapy is being evaluated in a planned randomized controlled trial to determine its efficacy in lowering LDL-C levels among patients with atherosclerotic cardiovascular disease.
Why the study?
Low compliance to lifestyle management limits the benefits of lipid reduction in ASCVD patients, prompting the evaluation of cognitive behavior therapy to improve outcomes.
Does mobile-based cognitive behavior therapy (CBT) reduce LDL-C levels in ASCVD patients receiving standard pharmacological treatments?
RCT (n=300)
Open-label
1:1 ratio
Yes
Does mobile-based cognitive behavior therapy (CBT) reduce LDL-C levels in ASCVD patients receiving standard pharmacological treatments?
Answers are grounded in this paper and cite their sources.
Planned RCT will test if mobile CBT lowers LDL-C beyond pharmacotherapy in ASCVD; leaves open role of digital behavioral therapy in lipid management.
BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) remains a major source of mortality in China. Convincing evidence has demonstrated that the reduction of low-density lipoprotein cholesterol (LDL-C) is correlated with lowering ASCVD risk. The efficacy of lifestyle management in lipid levels reduction has been confirmed in numerous studies. However, considering that low compliance to lifestyle management has limited the benefits of lowering lipid levels, cognitive behavior therapy (CBT) is proposed as a solution to improve clinical outcomes. The objective of this trial is to compare the LDL-C outcome in ASCVD patients receiving mobile device-based CBT to a control group, with both groups under standard pharmacological treatments. METHODS: This trial is designed as a multicenter, prospective randomized controlled trial with a 6-month follow-up. Mean LDL-C level and the percentage of different LDL-C levels, coefficient of variation of LDL, General Self-Efficacy Scale (GSEs), quality of life index (QL-index), etc., between the two groups at baseline, 1, 3, and 6 months will be measured. DISCUSSION: This trial should demonstrate that the implementation of mobile-based CBT intervention will be potentially effective in lowering LDL-C levels in ASCVD patients. TRIAL REGISTRATION: Chinese Clinical Trial Registry ( ChiCTR2100046775 ) [registered: 2021/5/28].
No takes yet. Share an insight, caveat, or question.
Hong et al. (2022) conducted an RCT in Atherosclerotic cardiovascular disease (ASCVD) (n=300). Mobile-based cognitive behavior therapy (CBT) vs. Conventional lifestyle intervention was evaluated on Mean change in LDL-C level. Mobile-based cognitive behavior therapy is being evaluated in a planned randomized controlled trial to determine its efficacy in lowering LDL-C levels among patients with atherosclerotic cardiovascular disease.
Synapse has enriched 10 related papers. Consider them for comparative context: